Innovate Biopharmaceuticals (INNT) Competitors

Syros Pharmaceuticals (NASDAQ:SYRS) and Innovate Biopharmaceuticals (NASDAQ:INNT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Is SYRS or INNT more profitable?

Innovate Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Innovate Biopharmaceuticals	N/A	N/A	-234.42%

Which has more volatility & risk, SYRS or INNT?

Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Innovate Biopharmaceuticals has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500.

Do institutionals and insiders have more ownership in SYRS or INNT?

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Innovate Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer SYRS or INNT?

Syros Pharmaceuticals presently has a consensus target price of $1.00, indicating a potential upside of 49,900.00%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Syros Pharmaceuticals is more favorable than Innovate Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syros Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Innovate Biopharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has stronger valuation & earnings, SYRS or INNT?

Innovate Biopharmaceuticals has lower revenue, but higher earnings than Syros Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.14	-$164.57M	-$3.03	0.00
Innovate Biopharmaceuticals	N/A	N/A	-$27.05M	N/A	N/A

Does the media favor SYRS or INNT?

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Innovate Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Innovate Biopharmaceuticals	Neutral

Summary

Syros Pharmaceuticals beats Innovate Biopharmaceuticals on 7 of the 10 factors compared between the two stocks.